SCHEMBL22388

SCHEMBL22388

Cc1nc2ccccc2cc1C(N)=O

nearest known ligand 0.67

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 1/20 0.67
KDM4E B2RXH2 2/20 0.60
ALDH1A1 P00352 3/20 0.55
GAA P10253 1/20 0.55
HPGD P15428 1/20 0.55
STAT3 P40763 1/20 0.55
MAPT P10636 3/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
RAB9A P51151 1/20 0.52
HTT P42858 1/20 0.51
HSD17B10 Q99714 1/20 0.50
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
LMNA P02545 1/20 0.47
IRAK4 Q9NWZ3 1/20 0.45
NNMT P40261 1/20 0.45
PARP1 P09874 2/20 0.44
PPARA Q07869 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31443745 1.00 IKBKB (0.67) IKBKBKDM4EALDH1A1GAAHPGD
SCHEMBL4302924 0.84 ALDH1A1 (0.67) IKBKBKDM4EALDH1A1GAAHPGD
SCHEMBL30251636 0.84 ALDH1A1 (0.67) IKBKBKDM4EALDH1A1GAAHPGD
SCHEMBL7915323 0.84 SMN1; SMN2 (0.59) IKBKBKDM4EALDH1A1GAAHPGD
Hydrochloric Acid SCHEMBL10504906 0.82 ALDH1A1 (0.65) IKBKBKDM4EALDH1A1GAAHPGD
SCHEMBL28115811 0.82 ALDH1A1 (0.65) IKBKBKDM4EALDH1A1GAAHPGD
SCHEMBL29538 0.80 IKBKB (0.69) IKBKBKDM4EALDH1A1GAAHPGD
SCHEMBL31060123 0.80 IKBKB (1.00) IKBKBKDM4EALDH1A1GAAHPGD
SCHEMBL30837 0.80 IKBKB (1.00) IKBKBKDM4EALDH1A1GAAHPGD
SCHEMBL2099350 0.80 IKBKB (0.69) IKBKBKDM4EALDH1A1GAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8513421-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-08-20 US claimed
EP-2569285-A1 BIFUNCTIONAL QUINOLINE DERIVATIVES Gilead Sciences, Inc. (US) 2013-03-20 EP claimed
WO-2011143105-A1 BIFUNCTIONAL QUINOLINE DERIVATIVES GILEAD SCIENCES, INC. (US) 2011-11-17 WO claimed
CN-109890793-A Novel anthelmintic quinoline-3-carboxamide derivatives 拜耳动物保健有限责任公司 2019-06-14 CN disclosed
CN-105130954-B 3,4 26 pyridylquinolines compounds of substitution and preparation and application 浙江大学 2017-10-31 CN disclosed
EP-2609085-A1 SUBSTITUTED QUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS Grünenthal GmbH (DE) 2013-07-03 EP disclosed
US-8445512-B2 Substituted quinoline-3-carboxamides as KCNQ2/3 modulators GRUENENTHAL GMBH (DE) 2013-05-21 US disclosed
US-20120053204-A1 Substituted quinoline-3-carboxamides as KCNQ2/3 modulators GRUNENTHAL GMBH (DE) 2012-03-01 US disclosed
WO-2012025238-A1 SUBSTITUTED QUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS Grünenthal GmbH (DE) 2012-03-01 WO disclosed
US-20110288117-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-11-24 US disclosed
WO-2011146591-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053204-A1 Substituted quinoline-3-carboxamides as KCNQ2/3 modulators KCNQ1, KCNQ2, KCNQ3 IKBKB 1088/4885KDM4E 810/4885ALDH1A1 3085/4885
US-20110288117-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC1, HDAC5 IKBKB 315/4885KDM4E 883/4885ALDH1A1 487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.